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The adipocyte plasma membrane-associated protein APMAP is expressed in the brain where it associates with γ-
secretase, a protease responsible for the generation of the amyloid-β peptides (Aβ) implicated in the pathogenesis
of Alzheimer’s disease (AD). In this study, behavioral investigations revealed spatial learning and memory
deficiencies in our newly generated mouse line lacking the protein APMAP. In a mouse model of AD, the
constitutive deletion of APMAP worsened the spatial memory phenotype and led to increased Aβ production and
deposition into senile plaques. To investigate at the molecular level the neurobiological functions of APMAP
(memory and Aβ formation) and a possible link with the pathological hallmarks of AD (memory impairment and Aβ
pathology), we next developed a procedure for the high-grade purification of cellular APMAP protein complexes.
The biochemical characterization of these complexes revealed a series of new APMAP interactomers. Among these,
the heat shock protein HSPA1A and the cation-dependent mannose-6-phosphate receptor (CD-M6PR) negatively
regulated APP processing and Aβ production, while clusterin, calnexin, arginase-1, PTGFRN and the cation-
independent mannose-6-phosphate receptor (CI-M6PR/IGF2R) positively regulated APP and Aβ production. Several
of the newly identified APMAP interactomers contribute to the autophagy-lysosome system, further supporting an
emergent agreement that this pathway can modulate APP metabolism and Aβ generation. Importantly, we have
also demonstrated increased alternative splicing of APMAP and lowered levels of the Aβ controllers HSPA1A and
CD-M6PR in human brains from neuropathologically verified AD cases.
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Evidence gathered over the past thirty years has im-
plicated the amyloid-β peptides (Aβ) as the causative
agents in the pathogenesis of Alzheimer’s disease
(AD) [9, 16]. Enhanced production associated with
impaired clearance of Aβ and the consequent peptide
polymerization into soluble oligomeric and/or insol-
uble amyloid deposits is indeed a critical and early
event that triggers a succession of pathological reac-
tions including hyperphosphorylation of tau and for-
mation of neurofibrillary lesions, neuroinflammation,
and neuronal death, ultimately leading to dementia [2,
23, 24, 31, 51]. Since Aβ peptides are derived from
the proteolytic processing of the amyloid precursor
protein (APP) by γ-secretase [20, 22], inhibiting the
latter protease is a valuable approach that has been
extensively tested in the clinic to prevent and/or delay
the pathogenic effects of AD [38]. The significant ad-
verse effects described in clinical studies [53, 54] have
revealed the gaps and urgent needs in understanding
the molecular and cellular pathways that regulate the
activity of γ-secretase, APP processing and Aβ pro-
duction in early- and late-onset AD in order to de-
sign safe and potent drugs against AD.
Previously, in a study that aimed to characterize the
γ-secretase interactome, we have demonstrated that the
adipocyte plasma membrane associated protein
(APMAP, C20orf3), the expression of which is necessary
for the maturation of adipocytes to acquire their capacity
to store lipids [49], is also highly expressed in the brain,
where it can physically interact with the γ-secretase
complex and can function as a suppressor of Aβ produc-
tion [40].
In this study, we first generated a constitutive knock-
out APMAP mouse line (APMAP-KO) that we charac-
terized in a battery of morphologic and behavioral tests,
to investigate the physiological role of APMAP in vivo.
We next developed a procedure for the high-grade puri-
fication of cellular APMAP protein complexes and fur-
ther assessed the ability of newly identified
APMAP-interacting proteins (AIPs) to modulate APP
processing and Aβ production. Finally, we investigated
the physiological relevance of our findings in human
brains from neuropathologically verified AD cases.
Materials and methods
Generation of the APMAP-KO and APMAP-KO/AD mouse
lines
Embryonic stem cells (ESCs) carrying the APMAP
exon 4 as described in the knockout-first construct
(see Additional file 1 Figure S1) and with the C57Bl/
6N genetic background were ordered from the Komp
repository (Apmaptm1a(KOMP)Wtsi, KOMP repository,
Davis, CA, USA). The transgene integration sites wereconfirmed by PCR and Southern blotting, and the
ESCs were injected into C57Bl/6N blastocysts and im-
planted into pseudo-pregnant females. The chimera
was bred for one generation with C57Bl/6N mice and
further inbred to obtain the full constitutive knockout
APMAP-KO mouse line and the control APMAP-WT
line. The forward primer 5’-AGAGGAGCTTATGA
GAGAGTTAATGG-3’ combined with the reverse pri-
mer 5’-TTGGTAAGAAAGGAAGCCAG-3’ were used
for the detection of the wild type allele (530 bp insert),
while the forward primer 5’-AGAGGAGCTTATGA
GAGAGTTAATGG-3’ combined with the reverse primer
5’-CCAACTGACCTTGGGCAAGAACAT-3’ were used
for the detection of the KO allele (726 bp insert). The
APMAP-KO/AD mouse line was generated by breeding
the APMAP-KO mice with the APPSwe-PS1dE9 mouse
model for AD [30], then inbred for one generation to ob-
tain a mouse line homozygous for APMAP-KO and het-
erozygous for the AD transgenes APPSwe-PS1dE9
(APMAP-KO/AD). Similarly, the control APMAP-WT
line was bred with the AD mouse line to generate the con-
trol APMAP-WT/AD mouse line. Since the APMAP-KO
and the APPSwe-PS1dE9 lines are of C57Bl/6J and C57Bl/
6N genetic backgrounds, respectively, the APMAP-KO/
AD line was maintained under a 1:1 mixed genetic back-
ground C57Bl/6N and C57Bl/6J. All mice were main-
tained at 23±1°C in a temperature-controlled facility, with
a 12h light/dark cycle and were fed ad libitum. All animal
experiments described in this study were approved by the
veterinary ethics committee of the canton of Vaud -
Switzerland (License IDs 2746).
Pathophysiological characterization of the APMAP-KO
mice
WT and APMAP-KO mice (chow or high fat diets,
5-9 months old) were euthanized by carbon dioxide
inhalation, and further dissected. All organs listed in
Additional file 1 Figure S2 were fixed for 48h in
formalin (Sigma Aldrich, Buchs, Switzerland) and
embedded in paraffin. Next, slices (4μm thickness)
were prepared by using a cryostat (Leica, Muttenz,
Switzerland), and subjected to Hematoxylin & Eosin
staining. Mounted slices were analyzed in a blind
fashion by two European board veterinary patholo-
gists (A.P. and C.G.).
Behavioral characterization of the APMAP-KO mice
Nine months old APMAP-KO mice underwent a
battery of behavioral tests, in a sequence intended to
prevent interferences between different tests. To avoid
phenotypes specific to one estrous cycle phase, female
mice of each experimental group were housed in several
cages, thus avoiding estrous cycle synchronization. The
Morris water maze test was performed to assess spatial
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[13, 59]. By using visual cues, mice had to learn the pos-
ition of an escape platform (11 cm diameter) submerged
0.5 cm below the water surface and set in the center of
the North quadrant of a circular pool (165 cm diameter).
Water was kept at 24±1°C and made opaque by adding
milk. The tank was placed in a room with artificial lighting
set at 55 lux. Mice received 4 training trials a day during
four days. Each trial started with a mouse released in the
pool from a different point, alternating release points close
and far from the escape platform. Mice not finding the
platform within a delay of 120 s were gently accompanied
to the platform and kept there for further 15 s. At the end
of each trial, the mice were placed under a heating lamp
for recovery in their home cages (inter-trial interval: 30
min). Retention of place learning was tested at day 5 with
a 120 s probe trial where the escape platform was re-
moved. Escape path lengths during training trials, and
time spent searching in the four quadrants during the
probe trial were assessed using a video tracking system
(EthoVision 3.0, Noldus, Wageningen, NL). The fear con-
ditioning test was performed to assess associative fear
learning and memory, as previously described [46]. During
the training session (1st day), the mice were placed in a
conditioning chamber (Med Associates inc., Fairfax,
VT, USA) where a tone (5000 Hz, 80dB) was presented
for 30 s, and a foot-shock (0.7mAmp) delivered during
the last 2 s of the tone presentation. Tone/foot-shock
pairings were repeated four times. The second day,
mice were placed in the same chamber and the freez-
ing responses to the context, in absence of the tone/
foot-shock, was monitored by using a video tracking
system (EthoVision 3.0). The third day, the same mice
were one more time exposed to the tone in a different
context (Med Associates inc., Fairfax, VT, USA), and
the freezing response to the auditory cue was assessed
as described above.
Proficiency in incidental learning and short-term
memory was assessed with the novel object recognition
task [21]. Briefly, after familiarization to a white square
arena (50 × 50 × 37 cm), mice were presented with two
identical plastic objects to explore during 10 minutes.
After 3h, mice were re-introduced in the same arena and
presented with one identical and one novel object,
placed in the same positions as in the previous presenta-
tion. Time spent in close proximity with the objects was
assessed by a video tracking system. Novelty recognition
results in increased contacts with the novel as compared
to the familiar object. The elevated plus maze test was
used to assess anxiety phenotypes, as described in previ-
ous studies [3, 17]. The maze was set-up 74 cm above
the floor, with two open (stressful) and two enclosed
(protecting) arms, designed in such a way that the arms
of the same type are facing each other and remainconnected by an opened central platform. In this test,
security is provided to the mice by the closed arms (19
cm high side walls) whereas the open arms offer ex-
ploratory value. To prevent mice slipping off the maze,
open arms have 0.5 cm high plexiglas rims. For the test,
mice were placed in the central area and allowed to ex-
plore the maze for 10 min. A video tracking system
(EthoVision 3.0) allowed the recording of the time spent
in each arm. The open-field test was performed to assess
exploration and locomotion, as described previously
[56]. Briefly, mice were released in the center and left to
freely explore a novel white square arena (50 × 50 × 37
cm), under dim light conditions (25 lux). Distance trav-
eled, as well as time spent in the center (stressful) and
peripheral (protecting) zones of the arena were recorded
during 30 min by using a video tracking system (EthoVi-
sion 3.0).
Place learning and spatial memory in APMAP-KO/AD mice
Cognitive proficiency was assessed in the
APMAP-KO/AD mice at the age of 20 months, in
the Morris water maze. Due to the expected lower
proficiency of these mice, the protocol used for the
APMAP-KO mice and described above was simpli-
fied as follows: mice were tested in a smaller pool
(150 cm diameter) using a slightly larger platform
(14 cm). In order to prevent fatigue, and improve
learning, maximal escape latencies were shortened to
90 s, and mice underwent 6 instead of 4 learning
trials per day. Consequently, the results in Fig. 1
and Fig. 2 shall not be compared directly. Path
lengths to reach the platforms during training trials,
and time spent in quadrants during the probe trial
were assessed using a different video tracking system
(AnyMaze, Ugo Basile, Varese, Italy).
Immunohistochemistry and Aβ plaque quantification
Nine month-old APMAP-KO/AD and their control
APMAP-WT/AD mice were euthanized and the brain’s
left hemispheres were collected, fixed for 48h in 4%
paraformaldehyde diluted in PBS (Roche), cryopro-
tected for 24h in 30% sucrose diluted in PBS, and kept
at -80°C in the cryopreservative matrix. Coronal hippo-
campal slices of 20μm thickness were obtained with a
cryostat, and further processed in a free floating man-
ner. First, slices were washed in PBS, boiled for 20 min
in citrate buffer (Invitrogen) and cooled at room
temperature. Next, blocking, binding of the primary
anti-Aβ 6E10 antibody (Biolegend, London, United
Kingdom) and binding of the secondary anti-mouse
HRP antibody, were performed with the Immpress kit
(Vector laboratories, Burlingame, CA, USA) according
to manufacturer instructions. Next, staining was per-
formed by using the SG-blue chromogen kit (Vector
Fig. 1 The constitutive deletion of APMAP selectively affects spatial memory but not anxiety, locomotion, fear-related or independent
hippocampus memories in WT mice. a, b In the Morris water maze, 9-month-old WT (+/+; n=11; 6 females and 5 males) and APMAP-KO mice
(ko/ko; n=13; 6 females and 7 males) show similar escape learning during training trials (repeated measures ANOVA: time effect F3,22=45,224,
*** p<0.001 Day 1 versus Day 4) (a). However, in the spatial memory probe test, after 4 days of acquisition training, APMAP-KO mice performed at
a chance level in the search for the platform, showing no preference for the target quadrant compared to WT control mice (b). c APMAP-KO
mice did not demonstrate a deficit in the acquisition or retention of a fear-conditioning task (repeated measures ANOVA F1, 22=0.112, p>0.05 for
genotype). d In an object recognition task, both groups spent more time exploring the novel object and were able to discriminate it from a
familiar object (repeated measures ANOVA F(1, 20)=13.175, ** p<0.01 familiar vs novel object, Tukey post hoc test. Genotype effect F(1, 20)=0.660
p>0.05, interaction genotype x object F(1, 20)=1.211 p>0.05). e In the elevated plus maze, WT and APMAP-KO mice exhibited a similar exploration
time on the open arms (repeated-measures ANOVA F(1, 19)=3.576, p>0.05 for genotype). f APMAP-KO mice did not exhibit a reduced locomotion
activity or an anxiety-related behavior compared to WT mice during an open field test (repeated-measures ANOVA F1,22=0.7, p>0.05 for
genotype). Data are expressed as the mean ± SEM
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Fig. 2 The constitutive deletion of APMAP worsens spatial memory and increases the hippocampal Aβ plaque load in AD mice. a, b In the Morris
water maze, 20-month-old Alzheimer’s disease (AD) mice depleted for APMAP (ko/ko AD; n=5; 2 females and 3 males) exhibited poorer escape
learning during training trials (repeated measures ANOVA: distance to platform, F3,21=8.426 *p<0.05 Day 1 versus Day 4; treatment effect
F1,21=7.290, #p<0.05 +/+ AD versus ko/ko AD at day 4) (a), and spent significantly less time in the target quadrant during probe test (b)
compared to AD control mice (+/+ AD; n=4; 1 female and 3 males). c Heat maps describing the spatial distribution of the two groups of animals
during the probe trial. Arrows indicate release points; the solid circle indicates the platform position. d Aβ1-40 peptides were estimated by ELISA
in whole brain SDS extracts prepared from the right hemispheres of 9-month-old APMAP-KO/AD mice (ko/ko AD; n=7 females) and age-matched
wild-type control littermates (+/+ AD; n=4 females). e The detection of Aβ plaques was performed by immunohistochemistry (IHC) in the
hippocampi of the left hemispheres of the same mice as in (d). f Representative microscopic images of coronal sections of hippocampi stained
by IHC for the detection of Aβ deposits (in black). Student’s t-test was applied for statistical analyses in panels d and e, with * p<0.05
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Finally, individual Aβ plaques were scored on slices
mounted with fluorsave (Millipore, Schaffhausen,
Switzerland) and analyzed by phase contrast micros-
copy (Zeiss, Feldbach, Switzerland).
Cell Lines and Cultures
Human embryonic kidney cells (HEK 293T) and hu-
man cervical carcinoma cells (HeLa) cells were rou-
tinely grown on plates in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% fetal bovine serum (FBS)and penicillin/streptomycin in a humidified 5% CO2
atmosphere. The CHO cells stably expressing
Flag-tagged APMAP and the HEK cells stably ex-
pressing APP with the Swedish mutation
(HEK-APPSwe [19]) were maintained in DMEM with
10% FBS supplemented with 150 μg/ml Geneticin
G418. DMEM, FBS, Penicillin-Streptomycin and G418
sulfate were purchased from Invitrogen (Carlsbad,
CA, USA). To adapt the CHO cells stably expressing
Flag-tagged APMAP for small-scale (less than 50 ml)
cultures in suspension, cells were inoculated at a
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pre-warmed medium (Lonza Verviers, Verviers,
Belgium) containing 1% FBS in CultiFlask 50 tubes
(Sartorius AG, Göttingen, Germany). The cultures
were agitated for 3-4 days by orbital shaking at 180
rpm in an ISF-4-W incubator (Kühner AG, Birsfelden,
Switzerland) at 37°C in the presence of 5% CO2 [41].
Large-scale 10-liter suspension cultures in ProCHO5
medium were performed in six 5-liter bottles (1.7 L
per bottle) and agitated at 110 rpm at 37°C as above.
Purification of APMAP and associated proteins from CHO-
APMAP1-Flag cells
The multi-step procedure for the high-grade purifica-
tion of native APMAP1 and associated proteins was
performed as previously described for the purification
of the γ-secretase complex [12]. Briefly, a total of
2.64 x 109 CHO cells stably transfected with human
APMAP1-Flag were resuspended in MES buffer (50
mM MES pH 6.0, 150 mM NaCl, 5 mM MgCl2, 5
mM CaCl2, and protease inhibitor cocktail (Roche)).
The cells were lysed by three passages in a
high-pressure homogenizer at a pressure greater than
1000 psi and centrifuged at 3000 x g for 20 min. The
supernatant was further centrifuged at 100,000 x g
for 1h to pellet membranes. The pellet was resus-
pended in bicarbonate buffer (0.1 M NaHCO3, pH
11.3) and incubated for 20 min at 4°C to remove
non-integral proteins. The washed membranes were
recovered by centrifugation at 100,000 x g for 1h.
The supernatant was discarded, and the membranes
were solubilized for 1h at 4°C in ice-cold lysis buffer
(50 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 5 mM
CaCl2) containing 1% of 3-([3-Cholamidopropyl]di-
methylammonio)-2-hydroxy-1-propanesulfonate (CHA
PSO; Sigma-Aldrich, Steinheim, Germany), and a pro-
tease inhibitor cocktail (Roche, Basel, Switzerland).
The lysate was centrifuged at 16,000 x g, saved, and
diluted twice in HEPES buffer (50 mM HEPES, 150
mM NaCl, 5 mM MgCl2, 5 mM CaCl2, and protease
inhibitor cocktail (Roche)). The lysate was further di-
luted six times in 0.1% digitonin-TBS buffer (50 mM
Tris-HCl pH 7.4, 150 mM NaCl) and bound to M2
anti-Flag affinity resin (Sigma Aldrich) overnight. Fol-
lowing three washes in 0.1% digitonin-TBS buffer, the
bound proteins were eluted in 1.5 ml of 0.1%
digitonin-TBS buffer containing 0.2 mg/ml Flag pep-
tides and finally subjected to size exclusion chroma-
tography, as described below.
Size exclusion Chromatography
The size exclusion chromatography of APMAP1 and
associated proteins was performed on a Superdex 200
10/300 GL column (GE Healthcare, Wauwatosa, WI,USA), as previously described [40]. Briefly, the two
APMAP fractions successively eluted from the M2
anti-Flag affinity resin (150 μl after 20-fold concentra-
tion) were loaded and eluted with 0.1% digitonin-TBS
at 0.3 ml/min. The column was calibrated with sol-
uble standards blue dextran 2000 (void volume),
thyroglobulin (669 kDa) and ferritin (440 kDa), which
were purchased from GE Healthcare (Wauwatosa, WI,
USA).Tryptic digestion and mass spectrometry
The fractions collected after the size exclusion chroma-
tography were run on a NativePAGE Novex® Bis-Tris
4-16% gel for BN-PAGE analysis (Invitrogen, Carlsbad,
CA) and the APMAP-containing complexes were visual-
ized by Silver staining, excised, and cut into small pieces.
Proteins were reduced, alkylated, and subjected to in-gel
digestion with trypsin. Briefly, gel pieces were destained,
desiccated by incubating twice in 200 μl of 50 mM am-
monium bicarbonate and 50% ethanol for 20 min, and
dried with a vacuum concentrator. The samples were
then incubated overnight at 37°C with trypsin (12.5 ng/
μl). For liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS) analysis after extraction from
gel slices, peptides were resuspended in 2% Acetonitril /
0.1% Formic Acid and separated by reverse-phase chro-
matography on a Dionex Ultimate 3000 RSLC
nanoUPLC system connected in-line with an Orbitrap
Elite (Thermo Fischer Scientific, Waltham, MA). The in-
strument was operated in an information-dependent
mode where peptide masses were selected for
collision-induced dissociation (CID) to generate tandem
mass spectra. A database search was performed using
Mascot 2.3 (Matrix Science, Boston, MA) and SEQUEST
in Proteome Discoverer v.1.3 against a human database
(UniProt release 2013_01; 87613 sequences) and Mam-
malian database (UniProt release 2011_07; 91104 se-
quences). All searches were performed with trypsin
cleavage specificity, with up to 3 missed cleavages
allowed, an ion mass tolerance of 10 ppm for the precur-
sor, and 0.5 Da for the fragments. Carbamidomethylation
was set as a fixed modification, whereas oxidation (M),
acetylation (protein N-term), and phosphorylation (STY)
were considered variable modifications. Data were
further processed and inspected using the proteome
software Scaffold 3.siRNA treatments
For siRNA knockdown experiments, cells were treated
for 3 days with the siRNAs listed in the table below. All
siRNA duplexes were complexed with Lipofectamine
RNAiMax from Invitrogen.
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For Western blot analysis of mouse brain APMAP and
associated proteins, brain total protein extracts were
prepared in a 50 mM HEPES pH7.0 buffer (1mL/100mg
tissue) containing 1% NP40 and a complete protease in-
hibitor cocktail (Roche). After tissue dissociation with a
Bounce Homogenizer and centrifugation at 17’000g for
30 min at 4°C, the supernatant was collected and the
equivalent of 40 μg of total proteins were loaded onto a
12% acrylamide Tris-Glycine gel and further resolved by
SDS-PAGE and transferred onto nitrocellulose mem-
branes. Next, the proteins APMAP and β-actin were de-
tected by using anti-APMAP (4F6, AbCam, Cambridge,
UK) and anti-β-actin (Sigma-Aldrich, Saint Louis, MS,
USA) antibodies respectively. The secondary antibodies
conjugated to Alexa 680 were purchased from Invitro-
gen, and the Odyssey infrared imaging system (LICOR,
Lincoln, NE, USA) was used to detect the fluorescent
signal. For Western blot analysis of cellular APMAP and
associated proteins, whole cell extracts were prepared in
50 mM HEPES buffer containing 1% NP40 and complete
protease inhibitor cocktail (Roche) and were run on 12%
Tris-glycine PAGE gels, transferred onto PVDF mem-
branes and probed with: antibody HPA012863 (for
APMAP, 1:2000, Sigma-Aldrich, St. Louis, MO), A206
(for Actin, 1:2000, Sigma-Aldrich), CT15 (for APP-FL
and APP-CTFs, 1:1000, Sigma-Aldrich), MAB1563 (for
PS1-NTF, 1:1000, Chemicon International, Temecula,
CA), Ab1997 (for ADAM10, 1:1000, Abcam, Cambridge,
MA), EE-17 (for BACE1, 1:1000, Sigma-Aldrich, St.
Louis, MO), AF5868 (for Arginase 1, 1:2000, R&D Sys-
tems, Minneapolis, MN), sc-6419 (for Clusterin alpha,
1:1000, Santa Cruz Biotechnology, Dallas, TX), AF1663
(for HSPA1A, 1:2000, R&D Systems), ADI-SPA-865-D
(for Calnexin, 1:1000, Enzo, New York, NY), PA5-51134
(for PTGFRN, 1:1000, Thermo Fisher, Waltham, MA),AF5320 (for M6PR-CD, R&D Systems), AF2447 (for
M6PR-CI, R&D Systems). Same approach was used for
the Western blot analysis of APMAP and associated pro-
teins in human frontal cortex tissue lysates.
Aβ40 and Aβ42 quantitative assays by ELISA
Aβ1-40 and Aβ1-42 peptides secreted in the conditioned
medium of HEK-APPSwe cells treated were quantita-
tively measured by ELISA, according to the protocol
provided by the manufacturer (ELISA kits KHB3481 and
KHB3441, Invitrogen).
Human frontal cortex tissue lysates
Lysates from frontal cortex of frozen human brains from
neuropathologically verified AD cases (obtained from
the brain bank of the Alzheimer’s Disease Research
Centre (ADRC) at Massachusetts General Hospital) were
prepared by RIPA buffer with protease and phosphatase
inhibitor cocktail (Fisher Scientific) and calyculin A (Cell
Signaling Technology, Danvers, MA, USA), as described
previously [37]. Control cases were non-demented indi-
viduals who did not meet pathological diagnostic criteria
of AD or any other neurodegenerative diseases. More
information that includes age, gender, post mortem
interval (PMI), degree of pathology (Braak stages),
standardized and validated clinical, neuropsychological,
neuropathological and behavioral assessments of AD
(CERAD) are provided in Table 1.
Deglycosylation assays
RIPA-buffer was used for whole protein extraction of
frozen human frontal cortical samples. The extracted
proteins (1mg/mL) were then denatured by addition of
SDS (Final conc. 1%) and heating at 75°C during 10
minutes. The denatured proteins were incubated with
Peptide-N-glycosidase F (PNGase F; Sigma-Aldrich,
Table 1 Demographic and diagnostic features of the human brain cortical samples used in this study
Age, gender, post mortem interval (PMI), degree of pathology (Braak stages) and standardized/validated clinical, neuropsychological, neuropathological and
behavioral assessments of AD (CERAD) are provided for both control cases (left; non-demented individuals who did not meet pathological diagnostic criteria of
AD or any other neurodegenerative diseases), or AD cases (right)
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oligosaccharides from glycoproteins.
Label-free quantitative proteomics
The brain left hemispheres from 17 month old male
APMAP-KO (n=3) or WT (n=3) mice were homoge-
nized by using a Heidolph RZR2052 control device and
total proteins were extracted from the tissue in RIPA
buffer (150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxy-
cholate, 0.1% SDS, 50 mM Tris-HCl pH 8.0) and prote-
ase inhibitor cocktail (Roche). For each sample, 200 μg
of solubilized proteins were reduced and alkylated before
being loaded on 4-12% gradient gels (NuPAGE, Thermo
Fisher) for protein separation. After staining (Colloidal
Blue staining kit, Invitrogen LC6025), each gel lane was
cut into 10 slices, the proteins were in-gel digested with
trypsin (Promega) and the resulting peptide mixtures
were processed on STAGE tips and analysed by LC-MS/
MS [48, 52]. The LC-MS measurements were performed
on a LTQ-Orbitrap mass spectrometer coupled to an
EasyLC 1000 nanoflow-HPLC. Peptides were separated
on fused silica HPLC-column tip (I.D. 75 μm, New Ob-
jective, self-packed with ReproSil-Pur 120 C18-AQ, 1.9
μm to a length of 20 cm) using a gradient of A (0.1%
formic acid in water) and B (0.1% formic acid in 80%
acetonitrile in water). The mass spectrometer was oper-
ated in the data-dependent mode; after each MS scan
(mass range m/z = 375 – 1750; resolution: 60000) a
maximum of five MS/MS scans were performed using
normalized collision energy of 35% and a target value of
1000. The MS raw files were analysed using MaxQuant
Software version 1.4.1.2 [4] for peak detection, quantifi-
cation and peptide identification using a full length Uni-
Prot mouse database (April, 2016). Keratins and trypsin
were used as references. Carbamidomethylcysteine was
set as fixed modification and protein amino-terminal
acetylation, lysine acetylation and oxidation ofmethionine were set as variable modifications. The MS/
MS tolerance was set to 20 ppm and three missed cleav-
ages were allowed using trypsin/P as enzyme specificity.
Peptide and protein false discovery rate (FDR) based on
a forward and reverse database were set to 0.01, mini-
mum peptide length was set to 7 amino-acids, and mini-
mum number of unique peptides for identification of
proteins was set to one. The “match-between-run” op-
tion was used with a time window of 1 min. For
normalization the MaxLFQ algorithm, part of the Max-
Quant suite was used. Statistical analysis of all proteins
revealed 113 significantly altered proteins (T-test,
p-value < 0.05; all information provided in Additional
file 2 Table S1). In order to identify significantly
enriched GO terms (p-value < 0.05), the list of signifi-
cantly altered proteins was analyzed against the whole
list of detected proteins with the 1D enrichment tool in
Perseus [58].
Statistical analyses
For the behavioral analyses in Figs. 1 and 2, the re-
peated measures ANOVA test was applied for the
statistical analyses, and the statistical significance is
shown as P < 0.05 (one asterisks), P < 0.01 (two aster-
isks) or P < 0.001 (three asterisks). For the other fig-
ures, the unpaired student’s t-test (two-tailed) was
applied. All data are presented as mean ± SEM.
Results
APMAP-KO mice display spatial learning and memory
deficiencies
We first generated an APMAP-KO mouse line with the
knockout-first construct (Additional file 1 Figure S1) and
completed a detailed pathological inspection on 4–
9-month-old mice, which did not reveal any macroscopic
and/or microscopic morphological abnormalities in per-
ipheral and brain tissues (Additional file 1 Figure S2).
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system [28, 40], we next conducted several behavioral tests
to assess whether the deletion of this gene causes behav-
ioral alterations. Spatial learning and memory was
assessed in 9-month-old WT and APMAP-KO mice, in
the Morris water maze performed as described in the
Materials and Methods section. Mice from both groups
showed comparable proficiency in water escape learning,
significantly reducing their swim paths to the platform
over the four training days (Fig. 1a). However, in the probe
trial without a platform, performed 24 h after the last
training session, only WT mice showed spatial searching
in the target quadrant, while APMAP-KO mice performed
at the chance level (Fig. 1b). Together, these results dem-
onstrate spatial learning and memory deficiencies in
APMAP-KO animals. Other forms of learning, such as
Pavlovian conditioning and semantic memory, respectively
assessed in cued and contextual fear conditioning and in
an object recognition task, were not affected in the
APMAP-KO mice (Fig. 1c, and d). Moreover, APMAP de-
letion did not affect anxiety, mobility, or exploratory drive,
as estimated in the elevated plus maze and open field tests
(Figs. 1e, and f).
The constitutive deletion of APMAP worsens spatial
memory and Aβ plaque deposition in a mouse model of AD
We next generated an AD mouse model lacking the
APMAP gene (APMAP-KO/AD) by cross-breeding the
APMAP-KO mice with APP/PS1 mice coexpressing the
KM670/671NL Swedish mutation of human amyloid
precursor protein (APP) and the dE9 mutation of human
presenilin 1 (PS1), which develops parenchymal Aβ pla-
ques starting at the age of 6 months [30, 35]. In the
Morris water maze performed under simplified condi-
tions when compared to WT mice (smaller pool and
shorter trials - see Materials and Methods), the
APMAP-KO/AD mice were less proficient than their
control AD mice, with significantly longer swim paths
on day 4 of the training (Fig. 2a), as well as showing a
significantly lower target quadrant preference in the
probe trial (Fig. 2b). Indeed, while WT/AD mice were
sufficiently oriented on the target quadrant, APMAP-
KO/AD mice did not show any spatial searching during
the probe trial, demonstrating a more severe spatial
memory deficit (Fig. 2c). Furthermore, extensive bio-
chemical and immuno-histological analyses revealed a
20±4 % increase of cerebral Aβ1-40 levels (Fig. 2d) asso-
ciated with a 24±5 % increase of the hippocampal Aβ
plaque area in the AD mice lacking APMAP as com-
pared to the control AD mice (Figs. 2e, and f).
Altogether, our findings revealed subtle but important
roles of APMAP in the learning and memory processes
and in the production of Aβ peptides and their depos-
ition into senile plaques.Purification and identification of APMAP interacting
proteins
We next designed a multistep purification procedure for
the high-grade purification of APMAP and APMAP pro-
tein complexes (Fig. 3a). First, we generated, selected and
adapted for cultures in suspension a CHO cell line that
stably overexpressed APMAP1-Flag (Additional file 1
Figure S3). Then, large amounts of CHO-APMAP1-Flag
cells harvested from a 10 L suspension culture were ho-
mogenized in a French press and cellular membranes were
prepared by differential centrifugation and washing with a
bicarbonate buffer [10] to remove both residual cytosolic
proteins and peripheral membrane proteins [14], leaving
only integral or tightly associated membrane proteins. The
washed membranes were then solubilized in a buffer con-
taining 1% CHAPSO, and the Flag-tagged APMAP and
APMAP protein complexes were affinity purified follow-
ing a previously described M2 anti-Flag antibody
immuno-affinity procedure [40]. As a last purification
step, the proteins eluted from the M2 resin were separated
by size exclusion chromatography (SEC) and the fractions
enriched in APMAP (Fig. 3b) were further loaded onto a
Blue Native gel (BN-PAGE), which allows the detection of
APMAP protein complexes in their native conformations.
As shown in Fig. 3b, the BN-PAGE analysis of the SEC
fractions revealed APMAP-containing protein complexes
with apparent molecular masses ranging between ~60
kDa and ~650 kDa.
To identify proteins physically bound to APMAP, the
SEC fractions enriched in APMAP protein complexes of
different sizes (SEC fractions A15, B15, B14, B12 and B10
– see Fig. 3b) were resolved by preparative BN-PAGE and
stained with silver nitrate (Fig. 3c). The bands correspond-
ing to well-separated APMAP complexes (named CP1 to
CP8) were excised for protein content analysis by LC-MS/
MS mass spectrometry. A total of 13 APMAP-interacting
proteins were identified in two independent experiments:
fetuin-A, reticulon-4, calnexin, lysosome-associated mem-
brane glycoprotein 1 (LAMP-1), nicastrin, prostaglandin
F2 receptor negative regulator (PTGFRN), cation-
independent mannose 6-phosphate receptor (CI-M6PR/
IGF2R), clusterin, membralin, arginase-1, heat shock-
related 70 kDa protein 2 (HSPA1A), serpinB3 and 14-3-3
protein sigma (stratifin) (Fig. 3d; protein sequences and
peptides identified by LC-MS/MS are listed in Additional
file 1 Figure S4).
APMAP-interacting proteins modulate APP processing
and Aβ production
The identification of nicastrin and reticulon-4 in the puri-
fied APMAP complexes confirms our previous observation
that the proteins APMAP and reticulon-4 can physically
interact with the γ-secretase complex [40]. Since nicastrin
is the subunit of the γ-secretase complex that is
Fig. 3 Purification of APMAP protein complexes and identification of APMAP interacting proteins. a Schematic representation of the multistep
process designed for the purification of APMAP protein complexes and for the identification of APMAP interactomers. b Affinity purified APMAP
protein complexes of different sizes were separated by size exclusion chromatography (SEC) on a Superdex 200 10/300 GL column. The SEC
protein elution profile (top) revealed a protein distribution over 12 SEC fractions (A15 to B5), separated under denaturing conditions (SDS-PAGE)
and immunostained with an anti-APMAP antibody (middle) or separated by blue native-PAGE (BN-PAGE) on a 4-16% Bis-Tris gel, and
immunostained for APMAP (bottom). APMAP protein complexes appeared on the native gel as a low-molecular-weight complex (LMWC) of ~60
kDa and high-molecular-weight complexes (HMWCs) of ~150 to ~650 kDa. c Mass spectrometric identification of APMAP interacting proteins. The
APMAP-containing low- and high-molecular-weight complexes from selected SEC fractions A15, B15, B14, B12 and B10 were resolved by native-
PAGE on a 4-16% Bis-Tris gel, stained by silver nitrate, and the bands corresponding to eight different protein complexes (CP1 to CP8) were
excised for protein content analysis by LC-MS/MS mass spectrometry. d Summary table of APMAP-interacting proteins identified by LC-MS/MS in
CP1 to CP8. *Proteins and peptides identified by LC-MS/MS are listed in Additional file 1 Figure S4
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lar depletion by small interfering RNA (siRNA) impairs
both APP processing and Aβ production [8, 34]. By using a
similar approach, we have previously shown that a drasticdepletion of reticulon-4 was associated with increased
APP-C-terminal fragments (APP-CTFs) and Aβ1-40 levels
[40]. Based on these observations, nicastrin and reticulon-4
were omitted from further analysis in this new study.
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APMAP-interacting proteins can also modulate the pro-
cessing of APP and the production of the Aβ peptides, their
expression was reduced by siRNA in APP-overexpressing
HEK cells. Treatments with siRNAs targeting fetuin-A,
stratifin, membralin, LAMP-1 and serpinB3 did not impact
the levels or maturation of full-length APP (APP-FL),Fig. 4 APMAP interacting proteins are endogenous modulators of APP pro
APMAP-interacting proteins was mediated by siRNA in HEK cells overexpre
familial Alzheimer’s disease (HEK-APPSwe). After 3 days of treatment, whole
Western blot for the siRNA protein targets, APP-FL, APP-CTFs and APMAP. A
siRNA; APP-FL: APP full-length; APP-CTFs: APP-C-terminal fragments. siRNA
conditioned media of the siRNA-treated cells in (a) were used to quantitati
Note the correlation between APP-CTFs levels estimated by densitometric
of both Aβ1-40 and Aβ1-42. Student’s t-test was applied for statistical analy
***P < 0.001; Aβ40 and Aβ42: n = 6/group; APP-CTFs: n=3/groupAPP-CTFs, or APMAP (Additional file 1 Figure S5). In
contrast, siRNAs targeting the heat shock protein HSPA1A
and the cation-dependent mannose-6-phosphate receptor
(CD-M6PR; functional homolog of CI-M6PR/IGF2R)
caused a strong accumulation of APP-CTFs, while siRNAs
against clusterin, calnexin, arginase-1, PTGFRN and
CI-M6PR/IGF2R lowered APP-CTFs levels (Fig. 4a).cessing and Aβ production. a The knockdown of the indicated
ssing APP bearing the Swedish mutation that causes early-onset
cell extracts from biological triplicates were prepared and analyzed by
ctin served as a protein loading control. Scramble: allstar control
duplexes are listed in the Materials and Methods section. b The
vely measure, by ELISA, the secreted peptides Aβ1-40 and Aβ1-42.
analysis of the APP-CTFs Western blot bands in (a) and the production
sis; the significance is shown as the mean ± SEM, *P < 0.05; **P < 0.01;
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both APP-FL and APMAP (Fig. 4a) and none of the other
siRNA knockdowns of individual genes interfered with the
protein levels of α-, β- or γ-secretases, with the exception of
clusterin and CD-M6PR, which respectively reduced
ADAM10 levels and increased BACE1 levels (Additional
file 1 Figure S6).
Next, the production of Aβ peptides was investigated by
quantitatively measuring both Aβ1-40 and Aβ1-42 pep-
tides secreted in the conditioned medium of the
siRNA-treated cells. We found a strong correlation be-
tween the effects observed on intracellular APP-CTFs and
the production of both Aβ1-40 and Aβ1-42 (Fig. 4b).
Indeed, increased APP-CTFs observed with siRNAs tar-
geting HSPA1A and CD-M6PR were associated with in-
creased Aβ40 and Aβ42 levels, while reduced APP-CTFs
observed with siRNAs targeting clusterin, calnexin,
arginase-1, PTGFRN and CI-M6PR/IGF2R were associ-
ated with reduced Aβ40 and Aβ42 levels (Fig. 4b).Alterations of APMAP interacting proteins in AD human
brains
We next compared the protein profiles of APMAP and its
newly identified interactomers in lysates of human brain
cortical samples from neuropathologically verified AD
cases and age-matched non-AD controls (Table 1). First,
we found in the AD samples drastically enhanced levels
(by 367±102%) of APMAP2 (Figs. 5a, and b), a previously
reported alternative splice variant of APMAP1 that lacks
exons 3, 4 and 5 [28]. PNGaseF treatment of the human
lysates confirmed the glycosylation of APMAP1 and the
absence of glycosylation in APMAP2 (Fig. 5c and
Additional file 1 Figure S7), consistent with the unique
APMAP1 glycosylation site predicted at position N160
(Additional file 1 Figure S8) in exon 5 that is missing in
APMAP2 (Fig. 5d). Importantly, we also found in the AD
samples significantly reduced levels of HSPA1A and
CD-M6PR (the two negative regulators of Aβ production),
by 29±5% and 37±4%, respectively (Figs. 5e, and f). No
significant changes were found for the other APMAP-
interacting proteins (Additional file 1 Figure S9).Brain proteome changes in APMAP-KO mice
Finally, we applied label-free quantitative mass
spectrometry to profile the brain proteome of APM
AP-KO mice. This approach revealed 113 proteins dif-
ferentially expressed in the brains of APMAP-KO mice
(listed in Additional file 2 Table S1), thus suggesting
novel neurobiological functions for APMAP and the
APMAP interactome, including the regulation of
neuronal differentiation, mRNA splicing, and autophagy
(Fig. 6).Discussion
In this study, we show that the constitutive knockout of
APMAP affects the hippocampal-dependent episodic
memory, while other cognitive competences (procedural
learning, semantic and pavlovian associations) are spared
(Fig. 1). We also found that the deletion of APMAP in
an AD mouse model results in a worsening of the spatial
learning, and this in spite of a simplified water maze
procedure that allowed sufficient place learning for the
control AD mice (Fig. 2). We also demonstrate that the
lack of APMAP increased the production of Aβ peptides
and their aggregation into senile plaques in the hippo-
campus of an AD mouse model (Fig. 2). In order to in-
vestigate the molecular bases for these observations, we
decided to develop a procedure for the characterization
of the APMAP interactome. We found that cellular
APMAP is organized into protein complexes of different
sizes and we identified new APMAP interactomers,
some of which modulate APP processing and the pro-
duction of Aβ peptides (Figs. 3 and 4).
Amongst these, we identified nicastrin, a subunit of
the γ-secretase complex [11], further supporting our
previous observation that APMAP and the γ-secretase
complex can associate into a HMW protein complex
[40]. In addition, we identified reticulon-4 in APMAP
complexes. Reticulon-4 is a myelin-associated membrane
protein (also known as “Nogo”) that inhibits neurite out-
growth and limits plasticity in the healthy adult brain
and neuronal regeneration during brain injury (for a re-
view, see [57]). The co-purification of reticulon-4 with
γ-secretase [40], with the β-secretase BACE1 [42] and
with APMAP (this study) suggests potential microdo-
mains (likely in the trans-Golgi network) made of the
secretases, APP-FL and -CTFs, APMAP and reticulon-4.
Amongst the newly identified APMAP interactomers,
HSPA1A and CD-M6PR, together with APMAP, were
found to negatively regulate APP processing and Aβ pro-
duction (Fig. 4). In contrast, clusterin, calnexin, argin
ase-1, PTGFRN and CI-M6PR positively regulated APP
processing and Aβ production (Fig. 4). HSPA1A is a
major protein of the Hsp70 family made of molecular
chaperones that are critical for the cellular management
of environmental stresses by preventing or reversing ab-
normal protein folding or aggregation (for reviews see
[26, 29, 50]). Interestingly, recent studies have reported
that dysfunctions or inhibitions of HSPA1A cause neuro-
degeneration, mainly by affecting the structure and
function of the endosomes/lysosomes (for reviews, see
[45, 62]). These observations are of particular interest
since we found that reduced HSPA1A leads to increased
production of APP-CTFs and Aβ peptides (this study - see
Fig. 4), and since APMAP can regulate APP processing
and Aβ production through the lysosomal-autophagic sys-
tem [40]. Altogether, it is tempting to hypothesize that the
Fig. 5 Increased alternative splicing of APMAP and reduced HSPA1A and CD-M6PR in AD brains. a Increased alternative splicing variant APMAP2
in AD brains, as estimated by Western blot analysis of APMAP1 and APMAP2 in cortical lysates of 14 control brains and 14 neuropathologically
verified AD brains. Detailed demographic and diagnostic features of the human brain samples are provided in Table 1. Actin served as a loading
control. b Densitometric analysis of the APMAP1 and APMAP2 Western blot bands in (a). Student’s t-test with mean ± SEM, **P < 0.01.
c Denatured cortical lysates of control and AD brains treated in the presence (+) or absence (-) of PNGase. d Schematic representation of the
exons and introns of APMAP1 and APMAP2. The predicted glycosylation site in exon 5 at position N160 is shown. e Reduced HSPA1A and CD-
M6PR levels in AD brains, as estimated by Western blot analysis in the same samples as in (a). f Densitometric analysis of HSPA1A and CD-M6PR
(e) and other APMAP-interactomers Additional file 1 Figure S9 Western blot bands. Student’s t-test with mean ± SEM, **P < 0.01
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Fig. 6 Representation of gene ontology enrichment in mice with constitutive depletion of APMAP, according to biological process (a), molecular
function (b) and cellular compartment (c). Label-free quantitative proteomics (procedure described in details in the Materials and Methods
section) was used to identify proteins differentially expressed in the brains of APMAP-KO mice. Significantly enriched GO terms (p-value < 0.05)
were identified by comparing the list of 113 significantly altered proteins (Additional file 2: Table S1) against the whole list of 2747 detected
proteins (Additional file 2: Table S1) using the 1D enrichment tool in Perseus
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and APMAP may control APP processing and Aβ produc-
tion by modulating the lysosomal activity through some
yet unidentified molecular mechanisms.
The Prostaglandin F2 receptor negative regulator
PTGFRN (also known as CD9P-1) is a member of the
tetraspanin web that plays different biological functions
including cell migration and cell fusion (for a review see
[27]). Moreover, PTGFRN was recently identified in
purified γ-secretase preparations [40, 60] while its recep-
tor CD9 also co-immunoprecipitated with the active
γ-secretase complex [60]. In the present study, wedemonstrate for the first time that PTGFRN is part of
the APMAP interactome, and propose that this
association explains the functional role of PTGFRN in
the regulation of APP processing and Aβ production
(Fig. 4).
Clusterin is a major inflammatory-related apolipopro-
tein (Apolipoprotein J; ApoJ) that plays a protective role
against apoptosis, cell damage, or oxidative stress [61].
Notably, recent genome-wide association studies from
different groups have further uncovered clusterin vari-
ants that strongly associate with late-onset AD [25, 33].
Intriguingly, we found that reduced clusterin triggered
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the first time the existence of a common mechanism
co-stabilizing these proteins. Moreover, clusterin has
previously been reported to physically associate with the
paraoxonase PON1 [1, 32, 36] whereas the only proteins
sharing high sequence and structural homologies with
APMAP are the three members of the PON family [28].
Together, these observations suggest a possible physical
association between APMAP and clusterin, that regu-
lates Aβ production/secretion through a molecular
mechanism that needs further investigation, and that po-
tentially involves the recently discovered function for
clusterin in the biogenesis and activation of the
autophagy-lysosomal system [63].
Importantly, we further observed that the reduction of
CI-M6PR/IGF2R expression lowered APP-CTF/Aβ,
whereas reduction of CD-M6PR expression (a functional
homolog of CI-M6PR/IGF2R) caused a strong accumu-
lation of APP-CTF/Aβ. Although the two M6PRs share
common tasks that are essential for normal cellular
function, including the delivery from the trans-Golgi
network to the lysosomes of newly synthesized acid hy-
drolases [15], it is important to notice that the opposite
results that we observed for APP-CTF/Aβ (Fig. 4) pro-
vides evidence that the receptors can fulfill different
functions. Differences in the structural organizations of
both M6P receptors (reviewed in [15]) may for example
trigger the formation of separate transport vesicles hav-
ing their own functional properties.
Altogether, these observations support the notion that
several members of the APMAP interactome, including
APMAP, HSPA1A, CD-M6PR and clusterin, may pre-
vent Aβ production by developing interconnected func-
tions that promote autophagy/lysosomal activity and
facilitate the autophagy/lysosomal transport and degrad-
ation of the Aβ precursor protein substrates APP-CTFs.
Further supporting this notion, two studies from differ-
ent groups have recently revealed physical interactions
between APMAP and APP [55] as well as between
APMAP and the APP binding protein FE65 [43]. Even
more recently, the role of alternative splicing in aging has
emerged (for a review, see [7]) and alternative splicing
events associated with AD have recently been reported for
genes in the autophagy-lysosomal pathway [47]. In sup-
port to these observations, we found that the alternative
splicing process of APMAP was increased in the brains of
neuropathologically verified AD cases (Fig. 5).
Finally, a mass spectrometric-based quantitative ana-
lysis of the APMAP-KO brain proteome revealed more
neurobiological functions for the APMAP interactome
that include the regulation of neuronal differentiation,
mRNA splicing, and autophagy (Fig. 6). Because neur-
onal differentiation is required for memory formation [6,
18], the alteration of this function (Fig. 6) provides aplausible explanation for the reduced learning and
spatial memory phenotypes observed in APMAP-KO
mice (Figs. 1 and 2). In addition, the possible implication
of APMAP in neuronal differentiation (Fig. 6) together
with the known function of peripheral APMAP in the dif-
ferentiation of adipocytes [49], suggest a more general role
for APMAP in cellular differentiation. At the molecular
level, it was previously shown that the γ-secretase-
dependent processing of APP and several other known
substrates including the Notch-1 receptor or Neurexins
are critical events for neuronal differentiation [5, 39, 44].
Thus, the possibility exists that the APMAP interactome
may regulate neuronal differentiation through the modu-
lation of the processing, by γ-secretase, of many different
substrates. Further investigation is needed to verify this
hypothesis, with a first emphasis on the processing of the
Notch and Neurexin receptors.
Related to the above-described function for APMAP1
in protein trafficking, one can hypothesize that the in-
creased APMAP2 expression and altered APMAP inter-
actome observed in AD patients (Fig. 5) may potentially
be involved in APP/APP-CTFs mis-trafficking and over-
production of Aβ. Based on these observations, further
investigation is required to elucidate the potential role of
APMAP2 in Aβ production and in the etiology of AD.
More specifically, the role of APMAP2 in the regulation
of APP-CTFs/Aβ could be investigated through overex-
pression in cellular models of APMAP2 and simultan-
eously depletion of CD-M6PR and HSPA1A, to
recapitulate the phenotype observed in human AD brain
samples (Fig. 5). Moreover, a similar biochemical ap-
proach as that used for the elucidation of the APMAP1
interactome (Fig. 3) could be used for the comparison of
the isoform-specific APMAP1 and APMAP2 interac-
tomes. Next, the influence of the two splicing variants
APMAP1 and APMAP2 on the trafficking and process-
ing of APP and other γ-secretase substrates could be
assessed. Finally, a correlation study between the
APMAP2 expression and Aβ pathology, with a larger
panel of human samples, would make a stronger case
for the importance of APMAP in AD pathology.
Overall, the characterization in this study of the
APMAP interactome and the identification of new en-
dogenous modulators of Aβ production not only offer
new therapeutic targets for the development of new
treatments for neurodegenerative or memory disorders,
but they also help to better understand the pathobiologi-
cal processes of the sporadic, age-related forms of AD.
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do not affect APP-FL, APP-CTFs, or APMAP. Figure S6. Depletion of individual
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APMAP2. Figure S8. APMAP1 predicted N-glycosylation at residue Asn160,
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